Skip to Content

Elosulfase Alfa

In the US, Elosulfase Alfa (elosulfase alfa systemic) is a member of the drug class lysosomal enzymes and is used to treat Mucopolysaccharidosis Type IV.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category


Chemical Name

human N-acetylgalactosamine-6-sulfatase (chondroitinsulfatase, galactose-6-sulfate sulfatase, EC= dimer (139-139')-disulfide glycosylated (produced by CHO cells) (WHO )

Foreign Names

  • Elosulfasum alfa (Latin)
  • Elosulfase alfa (German)
  • Elosulfase alfa (French)
  • Elosulfasa alfa (Spanish)

Generic Names

Brand Names

  • Vimizim
    BioMarin, Canada; BioMarin, Czech Republic; BioMarin, Denmark; BioMarin, Estonia; BioMarin, Japan; BioMarin, Netherlands; BioMarin, Norway; BioMarin, United States; BioMarin Europe, France; BioMarin Europe, Lithuania; BioMarin Europe, Poland; BioMarin Europe, Romania; BioMarin Europe, Sweden; BioMarin Pharmaceutical, Australia
  • Vimizim 1 mg/ml
    BioMarin Europe, Hungary
  • Vimizim 1mg/ml
    BioMarin, Austria; BioMarin, Germany
  • Vimizim 5mg/5ml
    DRAC, Switzerland


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.